These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37010809)

  • 21. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
    Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE
    J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apparent Lack of
    Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
    Front Immunol; 2019; 10():3045. PubMed ID: 31998317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.
    Hyman DM; Diamond EL; Vibat CR; Hassaine L; Poole JC; Patel M; Holley VR; Cabrilo G; Lu TT; Arcila ME; Chung YR; Rampal R; Lacouture ME; Rosen N; Meric-Bernstam F; Baselga J; Kurzrock R; Erlander MG; Janku F; Abdel-Wahab O
    Cancer Discov; 2015 Jan; 5(1):64-71. PubMed ID: 25324352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis.
    Ballester LY; Cantu MD; Lim KPH; Sarabia SF; Ferguson LS; Renee Webb C; Allen CE; McClain KL; Mohila CA; Punia JN; Roy A; López-Terrada DH; John Hicks M; Fisher KE
    Hematol Oncol; 2018 Feb; 36(1):307-315. PubMed ID: 28219109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [BRAF V600E Mutation in Chinese Patients with Langerhans Cell Histiocytosis and Its Clinical Significance].
    Cheng XY; Li Y; Zhou J; Shu YG; Li XL; Fu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):526-32. PubMed ID: 25948218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Status of Langerhans cell histiocytosis in children and adults].
    Kudo K
    Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
    Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
    Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
    Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
    J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of the
    Stathi D; Yavropoulou MP; Allen CE; Abhyankar H; Scull B; Tsoli M; Andreakos E; Kaltsas G; Makras P
    Pediatr Hematol Oncol; 2022 Sep; 39(6):540-548. PubMed ID: 35139731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival.
    Bhatia P; Singh M; Sharma M; Sharma A; Kakkar N; Radhika S; Trehan A; Bansal D
    Blood Cells Mol Dis; 2020 May; 82():102356. PubMed ID: 32171112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
    Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.
    Satoh T; Smith A; Sarde A; Lu HC; Mian S; Trouillet C; Mufti G; Emile JF; Fraternali F; Donadieu J; Geissmann F
    PLoS One; 2012; 7(4):e33891. PubMed ID: 22506009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Langerhans Cell Histiocytosis Associated With Renal Cell Carcinoma Is a Neoplastic Process: Clinicopathologic and Molecular Study of 7 Cases.
    Agaimy A; Bonert M; Naqvi A; Wang C; Trpkov K; Dettmar P; Wintzer HO; Stoehr R; Hes O; Williamson SR; Gibson IW; Hartmann A
    Am J Surg Pathol; 2020 Dec; 44(12):1658-1665. PubMed ID: 32910018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
    Tran G; Huynh TN; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A circulating subset of BRAF
    Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
    Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
    Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
    Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    El Sissy FN; Lorillon G; Mandonnet E; Polivka M; Addle-Biassette H; Emile JF
    Clin Neuropathol; 2020; 39(2):64-69. PubMed ID: 31661070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.